Organogenesis Holdings Inc. Cash Flow Statement
ORGO|10 years of annual SEC 10-K data (FY2016-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 10 fiscal years. All figures from audited SEC 10-K filings.
Organogenesis Holdings Inc. generated $31M in operating cash flow and $7M in free cash flow in FY2025. Free cash flow margin was 1.5% of revenue.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $4.9M | $15.5M | $94.2M | $17.2M | -$38.7M | -$64.8M | -$8.4M | -$17.0M | -$208.7K | -$25.2K |
| Depreciation & Amortization | $10.4M | $5.8M | $5.8M | $4.4M | $3.8M | $3.3M | $3.6M | $5.7M | - | - |
| Operating Cash Flow | $30.9M | $24.9M | $62.0M | $5.5M | -$33.5M | -$60.6M | -$3.5M | -$4.9M | -$562.2K | -$562.2K |
| Capital Expenditures | $24.4M | $33.9M | $31.2M | $17.7M | $6.0M | $1.9M | $2.4M | $1.4M | - | - |
| Free Cash Flow | $6.6M | -$9.0M | $30.8M | -$12.2M | -$39.5M | -$62.5M | -$5.9M | -$6.2M | - | - |
| Share Buybacks | $25.5M | $0 | - | - | - | - | - | - | - | - |
| FCF Margin | 1.5% | -2.0% | 6.6% | -3.6% | -15.1% | -32.3% | -3.0% | -4.5% | - | - |